JP2024510260A - 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト - Google Patents

疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト Download PDF

Info

Publication number
JP2024510260A
JP2024510260A JP2023556949A JP2023556949A JP2024510260A JP 2024510260 A JP2024510260 A JP 2024510260A JP 2023556949 A JP2023556949 A JP 2023556949A JP 2023556949 A JP2023556949 A JP 2023556949A JP 2024510260 A JP2024510260 A JP 2024510260A
Authority
JP
Japan
Prior art keywords
human
compound
acth
cah
cortisol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510260A5 (enExample
Inventor
フェラーラ－クック，クリスティン
エス． クラスナー，アラン
Original Assignee
クリネティックス ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリネティックス ファーマシューティカルズ，インク． filed Critical クリネティックス ファーマシューティカルズ，インク．
Publication of JP2024510260A publication Critical patent/JP2024510260A/ja
Priority to JP2025157498A priority Critical patent/JP2026009936A/ja
Publication of JP2024510260A5 publication Critical patent/JP2024510260A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023556949A 2021-03-19 2022-03-16 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト Pending JP2024510260A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025157498A JP2026009936A (ja) 2021-03-19 2025-09-22 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163163310P 2021-03-19 2021-03-19
US63/163,310 2021-03-19
US202263298571P 2022-01-11 2022-01-11
US63/298,571 2022-01-11
PCT/US2022/020543 WO2022197798A1 (en) 2021-03-19 2022-03-16 Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025157498A Division JP2026009936A (ja) 2021-03-19 2025-09-22 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト

Publications (2)

Publication Number Publication Date
JP2024510260A true JP2024510260A (ja) 2024-03-06
JP2024510260A5 JP2024510260A5 (enExample) 2025-10-01

Family

ID=83321094

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023556949A Pending JP2024510260A (ja) 2021-03-19 2022-03-16 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト
JP2025157498A Pending JP2026009936A (ja) 2021-03-19 2025-09-22 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025157498A Pending JP2026009936A (ja) 2021-03-19 2025-09-22 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト

Country Status (11)

Country Link
US (2) US12280046B2 (enExample)
EP (1) EP4308553A4 (enExample)
JP (2) JP2024510260A (enExample)
KR (1) KR20230159443A (enExample)
AU (1) AU2022240609A1 (enExample)
BR (1) BR112023018816A2 (enExample)
CA (1) CA3211644A1 (enExample)
IL (1) IL305952A (enExample)
MX (1) MX2023010897A (enExample)
TW (1) TWI916531B (enExample)
WO (1) WO2022197798A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102695210B1 (ko) 2018-06-05 2024-08-13 크리네틱스 파마슈티칼스, 인크. 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도
BR112023018816A2 (pt) 2021-03-19 2023-10-31 Crinetics Pharmaceuticals Inc Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença
EP4634176A1 (en) * 2022-12-16 2025-10-22 Crinetics Pharmaceuticals, Inc. Crystalline melanocortin subtype-2 receptor (mc2r) antagonist
PE20260134A1 (es) * 2023-05-19 2026-01-21 Crinetics Pharmaceuticals Inc Composiciones y metodos para el tratamiento de la hiperplasia suprarrenal congenita

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200216415A1 (en) * 2018-06-05 2020-07-09 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284956A (en) 1988-09-06 1994-02-08 Hoffmann-La Roche Inc. Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US6890940B2 (en) 2001-06-29 2005-05-10 Kowa Co., Ltd. Bis(2-aryl-5-pyridyl) derivatives
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US20030158209A1 (en) 2001-10-09 2003-08-21 Neurocrine Biosciences Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US6664273B2 (en) 2001-11-26 2003-12-16 Schering Corporation Piperidine based MCH antagonists for treatment of obesity and CNS disorders
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2003068738A1 (en) 2002-02-11 2003-08-21 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
JP2005534632A (ja) 2002-05-10 2005-11-17 ニューロクライン バイオサイエンセズ， インコーポレイテッド メラノコルチンレセプターリガンドとしての置換ピペラジン
WO2004081643A1 (en) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
EP1460073A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
NZ544820A (en) 2003-08-11 2009-02-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
EP1663232B1 (en) 2003-09-09 2007-10-03 F. Hoffmann-La Roche Ag 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
EP1871762A2 (en) 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
CA2625877A1 (en) 2005-10-18 2007-04-26 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2303597C1 (ru) 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
KR101088239B1 (ko) 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PT2344474E (pt) 2008-09-02 2015-12-28 Novartis Ag Derivados de picolinamida como inibidores de cinase
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
EP2715754B1 (en) 2011-05-31 2015-07-29 Linak A/S Actuator
EP3233916A4 (en) 2014-12-19 2018-06-06 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
EP3199156A1 (de) 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
EP3480198B1 (en) 2016-06-30 2021-05-05 Riken Novel compound or pharmaceutically acceptable salt thereof
US11377436B2 (en) 2017-07-12 2022-07-05 The Brigham And Women's Hospital, Inc. EAAT2 enhancing molecules
SG11202003407VA (en) 2017-10-17 2020-05-28 Merck Patent Gmbh PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
WO2021091788A1 (en) 2019-11-07 2021-05-14 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
JP7672406B2 (ja) 2019-12-18 2025-05-07 クリネティックス ファーマシューティカルズ，インク． Ｇｅｍ－二置換ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP7651574B2 (ja) 2019-12-23 2025-03-26 クリネティックス ファーマシューティカルズ，インク． スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ，インク． 多嚢胞性卵巣症候群を処置するための方法および組成物
BR112023018816A2 (pt) 2021-03-19 2023-10-31 Crinetics Pharmaceuticals Inc Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença
WO2023163945A1 (en) 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
EP4634176A1 (en) 2022-12-16 2025-10-22 Crinetics Pharmaceuticals, Inc. Crystalline melanocortin subtype-2 receptor (mc2r) antagonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200216415A1 (en) * 2018-06-05 2020-07-09 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADRIAN JOHN CLARK ET AL.: ""ACTH Antagonists"", FRONTIERS IN ENDOCRINOLOGY, vol. 7, JPN6026018382, 5 August 2016 (2016-08-05), ISSN: 0005854100 *
DANIEL CUEVAS-RAMOS ET AL.: ""Update onmedical treatment for Cushing’s disease"", CLINICAL DIABETES AND ENDOCRINOLOGY, vol. 2, no. 16, JPN6025049646, 13 September 2016 (2016-09-13), ISSN: 0005745984 *
ESTELLE LOUISET ET AL.: ""Intraadrenal Corticotropin in Bilateral Macronodular Adrenal Hyperplasia"", NEW ENGLAND JOURNAL OF MEDICINE, vol. 369, no. 22, JPN6026018383, 28 November 2013 (2013-11-28), pages 2115 - 2125, ISSN: 0005854101 *

Also Published As

Publication number Publication date
US20250367190A1 (en) 2025-12-04
TWI916531B (zh) 2026-03-01
US12280046B2 (en) 2025-04-22
CA3211644A1 (en) 2022-09-22
IL305952A (en) 2023-11-01
EP4308553A4 (en) 2025-01-22
AU2022240609A1 (en) 2023-09-28
KR20230159443A (ko) 2023-11-21
US20220313691A1 (en) 2022-10-06
WO2022197798A1 (en) 2022-09-22
EP4308553A1 (en) 2024-01-24
MX2023010897A (es) 2023-09-27
TW202302108A (zh) 2023-01-16
BR112023018816A2 (pt) 2023-10-31
JP2026009936A (ja) 2026-01-21

Similar Documents

Publication Publication Date Title
US12280046B2 (en) Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
Mazziotti et al. Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects
Bagatell et al. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men
US20250281504A1 (en) Method for improving insulin insensitivity
JP6585625B2 (ja) 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2011021044A (ja) 片頭痛を処置するための方法
JP2020033354A (ja) 対象における慢性または解決不能な疼痛を処置するための、および／または痛覚閾値を高めるための方法、およびこれに用いる医薬組成物
de Miguel Novoa et al. Guidelines for diagnosis and treatment of adrenal insufficiency in adults
WO2012074774A1 (en) Methods for the treatment of fibromyalgia and chronic fatigue syndrome
Pluchino et al. One-year therapy with 10 mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu
WO2023163945A1 (en) Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
EP4076470B1 (en) Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
RU2302245C2 (ru) ПРИМЕНЕНИЕ (11β, 17β)-11-(1,3-БЕНЗОДИОКСОЛ-5-ИЛ)-17-ГИДРОКСИ-17-(1-ПРОПИНИЛ) ЭСТРА-4,9-ДИЕН-3-ОНА ПРИ ЛЕЧЕНИИ БОЛЬШОГО ДЕПРЕССИВНОГО РАССТРОЙСТВА
Karmazin et al. The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function.
CN117043146A (zh) 用于治疗疾病的黑皮质素亚型-2受体（mc2r）拮抗剂
EA052204B1 (ru) Применение антагониста рецептора меланокортина 2-го подтипа (mc2r) для лечения болезни кушинга или эктопического актг-синдрома (eas)
JP2009102346A (ja) グルココルチコイドレセプターに特異的なアンタゴニストを使用して、せん妄を処置する方法
LU506495B1 (en) 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS
AU2024253140A1 (en) Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of acth-dependent cushing's syndrome
KR20260011716A (ko) 선천성 부신 과형성증 치료를 위한 조성물 및 방법
Suvisaari 7 α-Methyl-19-Nortestosterone (MENT): Pharmacokinetics and Antigonadotropic Effects in Men
Mahmoud EFFECT OF AROMATASE INHIBITOR THERAPY ON PREDICTED ADULT HEIGHT IN PREPUBERTAL BOYS WITH IDIOPATHIC SHORT STATURE
MacLennan et al. Endocrine and Metabolic Effects of Drugs and Hormonal/Endocrine Manipulation of Non-endocrine Diseases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260805